MPH Health Care AG (93M1) AI Stock Analysis

• Market Cap: €79.42M
• Dividend Yield: 6.58%
• Average Volume (3M): 1.12K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.08
• Revenue Growth: 180.19%
• EPS Growth: -196.45%
• Country: DE
• Employees: 2
• Sector: Financial
• Sector Strength: 70
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -16.99
• Shares Outstanding: 4,281,384
• 10 Day Avg. Volume: 1,634
• 30 Day Avg. Volume: 1,123
• PEG Ratio: 0.36
• Price to Book (P/B): 0.35
• Price to Sales (P/S): 15.83
• P/FCF Ratio: 53.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: €20.00 ▲(9.29% Upside)

The stock's overall score is driven by strong financial stability and profitability, despite concerns over revenue fluctuations and cash flow volatility. Technical indicators suggest stable market conditions, while valuation is impacted by a negative P/E ratio, partially offset by a high dividend yield.

MPH Health Care AG Business Overview & Revenue Model

Company Description

MPH Health Care AG (93M1) is a leading healthcare company focused on the development, manufacturing, and distribution of innovative medical products and services. Operating primarily in the health technology and pharmaceuticals sectors, MPH Health Care AG specializes in creating solutions that enhance patient care and improve healthcare outcomes. The company's core offerings include medical devices, health management software, and pharmaceutical products aimed at various therapeutic areas.

How the Company Makes Money

MPH Health Care AG generates revenue through multiple streams, primarily from the sale of its medical devices and health management software. The company partners with hospitals, clinics, and healthcare providers to supply its products, often entering long-term contracts that ensure a steady flow of income. Additionally, MPH Health Care AG earns revenue from its pharmaceutical division by marketing and distributing proprietary drugs, which are often developed in collaboration with research institutions. Strategic partnerships with other healthcare entities and participation in government health programs also contribute to the company's financial performance, allowing it to expand its market reach and enhance product development capabilities.

MPH Health Care AG Financial Statement Overview

Summary

MPH Health Care AG demonstrates strong profitability and financial stability, with a solid equity position and effective cost management. However, revenue fluctuations and cash flow volatility are areas of concern. Continued focus on generating consistent cash flows will be crucial for maintaining financial health.

Income Statement

MPH Health Care AG has shown improvement in key profitability metrics over recent years. The gross profit margin is strong, and there is a consistent net profit margin indicating profitability. However, revenue has fluctuated significantly, with a notable decline in 2024. Despite these fluctuations, EBIT and EBITDA margins remain healthy, reflecting effective cost management.

Balance Sheet

The company's balance sheet is robust, with a high equity ratio and a low debt-to-equity ratio, indicating financial stability. The return on equity is impressive, reflecting efficient use of shareholder funds. The company has managed its liabilities well, maintaining a solid stockholders' equity position, which suggests strong financial health.

Cash Flow

Cash flow analysis reveals some concerns, particularly with operating cash flow being negative in recent years, although it has turned positive in the latest period. The free cash flow shows significant volatility, but recent improvements in free cash flow growth are positive. The ratios indicate a need for better alignment of cash flow generation with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-72.59M	6.11M	7.24M	6.85M	4.36M	-9.02M
Gross Profit	-72.59M	6.11M	125.94M	6.80M	4.01M	-9.45M
EBITDA	-37.87M	33.32M	30.36M	29.68M	-9.05M	-71.00M
Net Income	-115.23M	32.04M	29.54M	29.11M	-8.96M	-70.38M
Balance Sheet
Total Assets	218.84M	291.06M	266.35M	236.99M	198.00M	210.71M
Cash, Cash Equivalents and Short-Term Investments	2.65M	1.20M	5.10M	3.82M	4.44M	4.23M
Total Debt	11.72M	10.56M	13.05M	12.99M	4.05M	7.62M
Total Liabilities	13.72M	13.19M	15.39M	15.57M	5.69M	9.45M
Stockholders Equity	205.12M	277.87M	250.97M	221.42M	192.31M	201.26M
Cash Flow
Free Cash Flow	1.02M	1.83M	-2.02M	-170.41K	-1.28M	-3.36M
Operating Cash Flow	3.59M	1.83M	-2.02M	-164.79K	-1.28M	-3.36M
Investing Cash Flow	4.10M	3.40M	5.40M	-8.96M	6.37M	12.83M
Financing Cash Flow	-6.85M	-7.70M	7.74M	-3.02M	-3.61M	-10.90M

MPH Health Care AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:93M1, the sentiment is Positive. The current price of 18.3 is above the 20-day moving average (MA) of 18.03, above the 50-day MA of 18.06, and below the 200-day MA of 19.89, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 65.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:93M1.

MPH Health Care AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PSG	―	€379.20M	19.49	52.68%	0.16%	15.20%	6.77%
AJ91	―	€65.94M	11.24	15.57%	5.80%	8.24%	140.53%
Sector *	―	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
93M1	―	€79.42M	―	-43.43%	6.58%	180.19%	-196.45%
LIK	―	€111.00M	23.60	23.66%	―	0.21%	7.53%
APPH	―	€92.65M	138.68	2.09%	―	27.42%	―